Compare HBIO & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBIO | LTRN |
|---|---|---|
| Founded | 1901 | 2013 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 46.8M |
| IPO Year | 2000 | 2020 |
| Metric | HBIO | LTRN |
|---|---|---|
| Price | $6.10 | $3.83 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | 20.6K | ★ 206.3K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,176,000.00 | N/A |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $8.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $1.11 |
| 52 Week High | $7.50 | $5.74 |
| Indicator | HBIO | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 55.87 |
| Support Level | $5.91 | $3.09 |
| Resistance Level | $6.79 | $3.79 |
| Average True Range (ATR) | 0.34 | 0.36 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 25.40 | 41.43 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.